ArticleClinical epidemiology2016
A nationwide study of the epidemiology of relapsing polychondritis.
Article in Clinical epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 65 citations in OpenAlex.
- Evaluating clinical heterogeneity in relapsing polychondritis through unsupervised cluster analysis.Arthritis research & therapy · 2026Article
- Identifying quality of life domains and facets affected in relapsing polychondritis: a qualitative analysis for the development of a disease-specific health-related quality of life instrument.Orphanet journal of rare diseases · 2026Article
- What are risk factors for relapse in relapsing polychondritis? A retrospective study.Clinical rheumatology · 2026Article
- Ulcerative Colitis in a Patient With Auricular Chondritis and Sweet Syndrome: A Rare Case.Case reports in medicine · 2026Article
- Relapsing polychondritis with isolated tracheal involvement: Imaging findings on CT, MRI, and PET-CT: A case report and literature review.Radiology case reports · 2025Article
- Coexistence of Relapsing Polychondritis, Crohn's Disease, and Pyoderma Gangrenosum Treated Successfully with Adalimumab: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2025Review
- Demographic, clinical, treatment, outcome, and comorbidities of patients with relapsing polychondritis: experience from Brazilian tertiary center, and literature review.Advances in rheumatology (London, England) · 2025Review
- Relapsing Polychondritis With Palmoplantar Pustulosis: A Case Report.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2025Article
- Relapsing Polychondritis Associated With Thyroid Carcinoma: A First Malagasy Case.Case reports in otolaryngology · 2025Article
- Paediatric relapsing polychondritis coexisting with Sjögren's disease in a 10-year-old girl successfully treated with mycophenolate mofetil.Rheumatology advances in practice · 2025Article
- Comprehensive Interventional treatment for severe central airway collapse caused by Relapsing Polychondritis: A case report.Heliyon · 2024Article
- A multicenter study of long-term outcomes of relapsing polychondritis in Iran.Scientific reports · 2024Article
- Relapsing polychondritis: clinical updates and new differential diagnoses.Nature reviews. Rheumatology · 2024Review
- Bibliometric analysis of the global publication activity in the field of relapsing polychondritis during 1960-2023.Clinical rheumatology · 2023Review
- Progress and challenges in the use of blood biomarkers in relapsing polychondritis.Clinical and experimental immunology · 2023Review
- Development and validation of diagnostic and activity-assessing models for relapsing polychondritis based on laboratory parameters.Frontiers in immunology · 2023Article
- Innate immune responses in Behçet disease and relapsing polychondritis.Frontiers in medicine · 2023Review
- Coexistent Relapsing Polychondritis and Clinically Amyopathic Dermatomyositis: A Rare Association of Autoimmune Disorders.Case reports in rheumatology · 2023Article
- Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.RMD open · 2022Article
- Nationwide cross-sectional survey of patients with relapsing polychondritis in 2019 demonstrates reduction of airway involvement compared with that in 2009.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRelapsing polychondritis (RP) is a rare autoimmune inflammatory disease that attacks mainly cartilaginous structures or causes serious damage in proteoglycan-rich structures (the eyes, heart, blood vessels, inner ear). This study shows results regarding the epidemiology, progression, and associations of this highly variable disease by collecting all cases from a 124-million-person-year Central European nationwide cohort.
methodsWe used the Hungarian Health Care Database to identify all persons with possible RP infection. We followed patients who had International Classification of Diseases 10th edition code M94.1 at least once in their inpatient or outpatient records between January 1, 2002 and December 31, 2013 in Hungary. We classified these patients into disease severity groups by their drug consumption patterns between January 1, 2010 and December 31, 2013. We analyzed the regional distribution of RP incidences as well. Overall maps of comorbidity are presented with network layouts.
resultsWe identified 256 patients with RP among cumulatively 11.5 million registered inhabitants. We classified these patients into four severity classes as "extremely mild" (n=144), "mild" (n=22), "moderate" (n=41), and "severe" (n=4). Two additional groups were defined for patients without available drug data as "suspected only" (n=23) and "confirmed but unknown treatment" (n=22). The age and sex distributions of patients were similar to worldwide statistics. Indeed, the overall survival was good (95% confidence interval for 5 years was 83.6%-92.9% and for 10 years was 75.0%-88.3% which corresponds to the overall survival of the general population in Hungary), and the associations with other autoimmune disorders were high (56%) in Hungary. Almost any disease can occur with RP; however, the symptoms of chromosomal abnormalities are only incidental. Spondylosis can be a sign of the activation of RP, while Sjögren syndrome is the most frequent autoimmune association. Regional distribution of incidences suggests arsenic drinking water and sunlight exposure as possible triggering factors.
conclusionThe good survival rate of RP in Hungary is probably associated with the early diagnosis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.